LYEL compared with SPRO: revenue, margins and what each company keeps, and the suppliers and customers both name

LYELLyell Immunopharma, Inc.

Mkt capRevenueRevenue

SPROSpero Therapeutics, Inc.

Mkt capRevenueRevenue

Compare

LYELLyell Immunopharma, Inc.

SPROSpero Therapeutics, Inc.

Price

Mkt cap

Revenue

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Save comparison

Earnings history

News Findings Companies A–Z Pricing Methodology Sources Corrections About Terms

Not investment advice. Not a broker-dealer. Indices shown as ETF proxies. Supply-chain data CC BY 4.0; market data not redistributable.

Listed on One’s Vibe · live-checked · Oct ’26

Desk News Calendar Saved

Earnings history

last 4 reports each · paired by recencyMethod ›

LYEL1 of 4 reports

0 of 1at or beyond implied

Reportimpliedrealized× implied

Q2 FY26±35.4%▲+3.52%×0.10

SPRO1 of 4 reports

0 of 1at or beyond implied

Reportimpliedrealized× implied

Q2 FY26±64.1%▲+4.20%×0.07

= impliedLYEL realized, solidSPRO realized, hatchedOne scale, both sides: full bar = 65%× = |realized| ÷ impliedSource: market data

LYELLyell Immunopharma, Inc.

10.69· pre 10.69· delayed

Mkt cap$270.5MRevenue$4,000Q2 FY26Revenue$36,000FY25

SPROSpero Therapeutics, Inc.

1.07· pre 1.04· delayed

Pre-marketNov 2 '26delayed

Mkt cap$60.6MRevenue$258,000Q1 FY26Revenue$67MFY25

Compare

Pre-marketNov 2 '26delayed

LYELLyell Immunopharma, Inc.

SPROSpero Therapeutics, Inc.

10.69pre 10.69delayed

Price

1.07pre 1.04delayed

$270.5M

Mkt cap

$60.6M

Q2 FY26$4,000

Revenue

$258,000Q1 FY26

FY25$36,000

Revenue

$67MFY25

LYEL10.69vsSPRO1.07Pre-marketNov 2 '26delayed